Searched for
GLAND PHARMA CDMO BUSINESS GROWTH
Two Trades for Today: An auto sector major for a 6.25% upmove, a mid-cap pharma stock for a gain of almost 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities declined for a second session as investors stayed cautious despite easing geopolitical tensions. Sensex lost nearly 250 poi...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...
- 2 top stock recommendations from Vinay RajaniIndian equity markets are experiencing a cautious phase, consolidating within a defined range as fresh buying momentum remains elusive. Tec...
- Stocks in news: Waaree Energies, Kotak Bank, HDFC Bank, Strides Pharma, Persistent SystemsIndian markets showed volatility, ending nearly flat despite positive signals. Analysts note Nifty faces resistance from key moving average...
- The hidden reason global capital is looking beyond India for future growthForeign investors are reallocating capital away from India towards markets like Taiwan and South Korea that offer stronger exposure to AI a...
- Strides Pharma sells majority stake in arm Pivot Path for Rs 100 croreStrides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital ...
- Companies should focus on business growth, profitability rather than just share price: NSE chiefNSE MD and CEO Ashish Chauhan urged companies to prioritize building sustainable businesses and long-term value over solely chasing share p...
- NSE chief urges startups and MSMEs to view listing as a tool for scaleNational Stock Exchange MD and CEO Ashish Chauhan highlighted that profitable businesses are rewarded with valuations private markets can't...
- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- BHIM eyeing govt schemes, products to boost business growthLalitha Nataraj, chief executive officer of NPCI BHIM Services Ltd (NBSL), said the company is targeting largely untapped user segments and...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- Ahead of Market: 10 things that will decide stock market action on WednesdaySensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- India's defence export boom could hit ₹65,000 crore by 2030; pvt sector startups the real play: Sunil SubramaniamIndia's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...
- Banking, capital goods and midcaps seen driving market's next rally: Ashish ChaturmohtaIndian equities are poised for fresh highs, driven by strong earnings and sector-specific momentum, particularly in financials and manufact...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
Load More
